Reported positive interim Phase 1 results for SPY003, a next-generation anti-IL-23 antibody, demonstrating the molecule was well-tolerated and exhibited an ~85-day half-life supporting quarterly or twice annual maintenance dosing Initiated Phase 2 SKYWAY basket study of SPY072 evaluating TL1A inhibition in rheumatoid arthritis ("RA"), psoriatic arthritis ("PsA"), and axial spondyloarthritis ("axSpA") On track for 6 proof-of-concept readouts in 2026 across the SKYLINE and SKYWAY Phase 2 trials Further stren ...

SAN FRANCISCO, Nov. 04, 2025 (GLOBE NEWSWIRE) -- LiveRamp® (NYSE: RAMP), a leading data collaboration platform, today announced that its CFO Lauren Dillard will present at the Wells Fargo 9th Annual TMT Summit in Rancho Palos Verdes, CA on Tuesday, November 18th at 12:45 p.m. PT / 3:45 p.m. ET. Links to the live webcast of the presentation and a replay will be available on LiveRamp’s investor relations website. About LiveRamp LiveRamp is a leading data collaboration technology company, empowering marketers ...

DENVER, Nov. 04, 2025 (GLOBE NEWSWIRE) -- InnovAge Holding Corp. (“InnovAge” or the “Company”) (Nasdaq: INNV), an industry leader in providing comprehensive healthcare programs to frail, predominantly dual-eligible seniors through the Program of All-inclusive Care for the Elderly (PACE), today announced financial results for its fiscal first quarter ended September 30, 2025. “We’re off to a strong start in fiscal 2026,” said Patrick Blair, CEO. “Our results reflect disciplined execution, continued investmen ...

Latham Outperforms the U.S. In-Ground Pool Market With Strong Third Quarter ResultsNet Sales Growth of 7.6%, Including Organic Growth of 4.7%Gross Margin Expanded by 300 Basis Points Third Quarter 2025 Financial Highlights: Net sales of $161.9 million up 7.6%Net income of $8.1 million up 37.7% / Earnings per diluted share of $0.07 vs. $0.05 in prior yearAdjusted EBITDA of $38.3 million up 28.5% reaching 23.7% of net sales Nine Months 2025 Financial Highlights: Net sales of $446.0 million up 5.9%Net income ...

Than Powell Than Powell, CBO, Longeveron On track for top-line trial results in the third quarter of 2026 from pivotal Phase 2b clinical trial ELPIS II. ELPIS II is evaluating laromestrocel as a potential adjunct treatment for HLHS, a rare pediatric disease and orphan-designated indication and is fully enrolled.ELPIS II may serve as foundation for a Biologics License Application (BLA) submission for full approval for HLHS, if results demonstrate sufficient evidence of efficacyCompany to host conference ...

Operational efficiencies drive $15.0 million of year-to-date improved cash flow from operating activities and $13.2 million increase in adjusted EBITDA, strengthening the foundation for efficient growth aheadDENVER, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Inspirato Incorporated (“Inspirato” or the “Company”) (Nasdaq: ISPO), the premier luxury vacation club and property technology company, today reported results for the third quarter (“Q3 2025”) ended September 30, 2025. Q3 2025 Highlights: Net loss of $4.5 milli ...

NEW YORK, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that it has been named a BioSpace 2026 Best Place to Work. “Protara is thrilled to be recognized as one of the most sought-after biotech employers in the life sciences community,” said Jesse Shefferman, Chief Executive Officer of Protara Therapeutics. “Our colleagues are crucial to every aspect of ou ...

Core Insights - Paylocity Holding Corporation reported strong financial results for the first quarter of fiscal year 2026, with a 14% growth in recurring and other revenue and a significant increase in profitability, driven by its modern software offerings and AI strategy [2][3][7]. Financial Performance - Recurring and other revenue reached $378.9 million, up 14% year-over-year [7][8]. - Total revenue for the quarter was $408.2 million, reflecting a 12% increase compared to the same period last year [7][8]. - GAAP operating income was $74.2 million, compared to $64.1 million in the first quarter of fiscal year 2025 [3]. - Non-GAAP operating income increased to $121.2 million from $104.9 million year-over-year [3]. - GAAP net income was $48.0 million, or $0.86 per share, down from $49.6 million, or $0.88 per share, in the prior year [4]. Adjusted Metrics - Adjusted EBITDA for the quarter was $146.4 million, up from $129.0 million in the same quarter last year [9]. - Adjusted EBITDA excluding interest income on funds held for clients was $117.1 million, compared to $99.2 million in the prior year [9]. Balance Sheet and Cash Flow - Cash and cash equivalents totaled $165.2 million as of September 30, 2025 [9]. - Long-term debt stood at $81.3 million, with $81.3 million repaid during the quarter [9]. - Net cash provided by operations was $86.5 million, down from $91.5 million in the same quarter last year [10]. Share Repurchase and Financial Targets - The company repurchased $200 million worth of shares in the first quarter, totaling $500 million since May 2024 [7]. - Updated long-term financial targets include total revenue of $3 billion and an adjusted EBITDA margin of 40-45% [7]. Business Outlook - For the second quarter of fiscal year 2026, recurring and other revenue is expected to be between $378.5 million and $383.5 million, indicating approximately 10% growth [15]. - Total revenue guidance for the full fiscal year 2026 is projected to be between $1.715 billion and $1.730 billion, representing about 8% growth [15].

SAN DIEGO, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Kratos Defense & Security Solutions, Inc., a technology company in defense, national security, and global markets, announced today that it has signed a definitive agreement to acquire 100 percent of the ordinary shares of Orbit Technologies Ltd (ORBI.TA) for $356.3 million, which is expected to be funded via cash on Kratos’ balance sheet. Orbit is a leading global provider of mission-critical satellite-based communication systems for mobile and unmanned aerial, s ...

PORTLAND, Maine, Nov. 04, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced the start date of its new CEO and related board changes. Effective November 1, 2025, Olivier te Boekhorst began serving as President and CEO of the Company, succeeding Michael F. Brigham. At its ...